Key Points
- Insider purchase: Chief Accounting Officer Neil Lerner bought 20,000 Compass Therapeutics shares at an average of $0.92, investing $18,400 and increasing his holdings by 5% to 420,000 shares.
- Weak market performance: CMPX opened at $0.86, near its one-year low of $0.83, with its 50-day and 200-day moving averages at $1.98 and $2.73, respectively. The company also reported a quarterly EPS loss of $0.13, missing the $0.11 consensus estimate.
- Analyst outlook remains mixed but positive overall: Ratings range from strong sell to strong buy, though MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $10.21.
Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) CAO Neil Lerner bought 20,000 shares of the stock in a transaction on Thursday, October 1st. The shares were purchased at an average price of $0.92 per share, with a total value of $18,400.00. Following the acquisition, the chief accounting officer owned 420,000 shares in the company, valued at approximately $386,400. This represents a 5.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Neil Lerner also recently made the following trade(s):
- On Thursday, September 24th, Neil Lerner purchased 2,500 shares of Compass Therapeutics stock. The stock was purchased at an average cost of $1.14 per share, for a total transaction of $2,850.00.
Compass Therapeutics Price Performance
Shares of Compass Therapeutics stock opened at $0.86 on Friday. The firm has a market cap of $154.28 million, a price-to-earnings ratio of -2.14 and a beta of 1.02. The stock's 50-day moving average is $1.98 and its 200-day moving average is $2.73. Compass Therapeutics, Inc. has a one year low of $0.83 and a one year high of $6.88.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). On average, equities analysts expect that Compass Therapeutics, Inc. will post -0.47 EPS for the current year.
Hedge Funds Weigh In On Compass Therapeutics
A number of institutional investors have recently added to or reduced their stakes in CMPX. Parallel Advisors LLC acquired a new stake in Compass Therapeutics in the first quarter valued at $28,000. PNC Financial Services Group Inc. increased its stake in shares of Compass Therapeutics by 2,572.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company's stock worth $58,000 after purchasing an additional 10,625 shares during the last quarter. HB Wealth Management LLC acquired a new position in shares of Compass Therapeutics during the 2nd quarter worth about $29,000. State of Wyoming bought a new stake in shares of Compass Therapeutics in the 2nd quarter valued at about $31,000. Finally, Pictet Asset Management Holding SA bought a new stake in shares of Compass Therapeutics in the 1st quarter valued at about $76,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on CMPX shares. Wall Street Zen cut shares of Compass Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Citizens Jmp reduced their target price on shares of Compass Therapeutics to $4.00 and set a "market outperform" rating for the company in a report on Wednesday, September 23rd. Piper Sandler lifted their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Lifesci Capital downgraded shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 22nd. Finally, Citigroup restated a "market outperform" rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $10.21.
Check Out Our Latest Research Report on CMPX
Compass Therapeutics Company Profile
(
Get Free Report)
Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company's research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.
Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
